With the deadline for new regulations on serialisation looming closer for both the US and European markets, the biggest challenge many pharmaceutical companies face is time.

There might be some pharmaceuticals that can’t bear the costs that serialisation entails.

As of February 2019 (November 2017 for the US), all EU pharmaceutical companies must be set up to ensure full compliance with serialisation, which for many requires a large investment as well as internal changes to current work routines.

Our Director – Corporate Projects and Serialisation Programme Manager, Staffan Widengren, talks to Nordic Life Science about how early planning and experience has helped Recipharm prepare for the serialisation challenge ahead and what the new regulations mean to the drug market.

Read the full article here:

The race against the serialisation deadline